Even though 2013 is already under way and there is a constant influx of new information, we wanted to make this an opportunity to look back at 2012 and relive some of our most memorable posts. So here they are, the 5 posts of 2012 that we have deemed the most interesting. Enjoy!
What would a discussion on DNA Vaccines be with out a general understanding of what they are? This article provides an overview of DNA Vaccines, their advantages, disadvantages, and why we believe they have such enormous unrealized potential. If you’re new to our blog or DNA Vaccines, this is definitely the 2012 article to start with.
Not only was this an important milestone for Coridon and VGXI, this was one of our most viewed articles, ever! This article obviously struck a nerve with our viewers, giving those that suffer with Herpes the hope that one day they might not have to.
Since this article was published, I have not been able to find any updates on the progress of this “E-75” breast cancer vaccine. If you didn’t get a chance to read the article the first time around, check it out and let us know if you’ve heard any recent developments! We’d love to hear some good news from these trials in 2013!
While you can tell from the title that this article is not about DNA Vaccines, this represents a huge leap forward for therapeutic drug development in the Western World. The drug, Glybera, has since been approved for use in Europe and the company is seeking approval for use in North America as well. This still leads people to wonder, is this the proverbial straw that broke the camels back? Can we expect to see more gene therapies and therapeutic treatments hit the market in 2013?
We started off 2012 describing what DNA Vaccines are and listed some of their advantages, but what use is that information if there is nothing to compare them to? In this article, we divulge the secrets of both traditional vaccines and DNA Vaccines to provide an in-depth look at exactly why we believe DNA Vaccines are the new horizon for both therapeutic and preventive applications.